Phase 4 Osteoporosis Trial, Recruiting (NCT06558188)

Phase 4 Osteoporosis Trial, Recruiting NCT06558188 Sponsor: Massachusetts General Hospital Condition: Osteoporosis

Printed from Voxsanity (voxsanity.com.au) — NCT06558188 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Osteoporosis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Women who are 45 years of age or older
Women who have gone through menopause
Women who have been diagnosed with osteoporosis and are considered at high risk of bone fractures

Who may not be able to join:

Women who have previously used treatments that significantly affect bone health
Women with a known bone disease other than osteoporosis, whether present from birth or developed later in life
Women with serious kidney disease, liver disease, heart or lung disease, or psychiatric illness
Women with abnormal levels of calcium or parathyroid hormone in their blood
Women with low vitamin D levels in their blood (below 20 ng/dL)
Women with anaemia, indicated by a low haematocrit level (below 32%)
Women with a history of cancer, with the exception of certain non-aggressive skin cancers
Women with a history of heavy alcohol use or substance abuse
Women with known medical reasons why the study medications romosozumab or teriparatide would not be suitable for them (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Benjamin Leder, MD, MGH

Phone: 617-726-6129

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06558188

Sponsor: Massachusetts General Hospital

Phase: Phase 4

Status: Recruiting

Condition: Osteoporosis

Trial contact: 617-726-6129

More information: https://clinicaltrials.gov/study/NCT06558188

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Women who are 45 years of age or older
Women who have gone through menopause
Women who have been diagnosed with osteoporosis and are considered at high risk of bone fractures

Who may not be able to join:

Women who have previously used treatments that significantly affect bone health
Women with a known bone disease other than osteoporosis, whether present from birth or developed later in life
Women with serious kidney disease, liver disease, heart or lung disease, or psychiatric illness
Women with abnormal levels of calcium or parathyroid hormone in their blood
Women with low vitamin D levels in their blood (below 20 ng/dL)
Women with anaemia, indicated by a low haematocrit level (below 32%)
Women with a history of cancer, with the exception of certain non-aggressive skin cancers
Women with a history of heavy alcohol use or substance abuse
Women with known medical reasons why the study medications romosozumab or teriparatide would not be suitable for them (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 4

Sponsor

Massachusetts General Hospital

Registry

ClinicalTrials.gov

Start date

3 February 2025

Est. completion

30 December 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Lumbar spine areal bone mineral density

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov